
Quarterly report 2025-Q3
added 11-05-2025
Anika Therapeutics Net Debt 2011-2026 | ANIK
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Anika Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -46 M | -57.5 M | -75.1 M | - | -135 M | -89 M | -133 M | -104 M | -111 M | -100 M | -63.3 M | -34.5 M | -24.6 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -24.6 M | -135 M | -81.1 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.6 | 1.34 % | $ 8.66 B | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.66 | - | $ 16.7 M | ||
|
BioNTech SE
BNTX
|
-973 M | $ 91.28 | - | $ 27.2 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 4.48 | - | $ 736 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Cerus Corporation
CERS
|
-6.9 M | $ 1.85 | - | $ 353 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Coherus BioSciences
CHRS
|
-85.6 M | $ 1.67 | - | $ 196 M | ||
|
Celldex Therapeutics
CLDX
|
-26.5 M | $ 31.37 | - | $ 2.08 B | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
-5.64 M | $ 0.44 | - | $ 5.04 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
CNS Pharmaceuticals
CNSP
|
-13.6 M | $ 2.32 | - | $ 1.03 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Catalyst Pharmaceuticals
CPRX
|
-706 M | $ 24.98 | - | $ 3.05 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
263 K | $ 10.14 | - | $ 135 M | ||
|
Cardiff Oncology
CRDF
|
-16.6 M | $ 1.58 | - | $ 106 M | ||
|
Curis
CRIS
|
-3.44 M | $ 0.53 | - | $ 6.98 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-53 M | $ 37.7 | - | $ 3.55 B | ||
|
CRISPR Therapeutics AG
CRSP
|
-141 M | $ 49.15 | - | $ 4.42 B | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
CytomX Therapeutics
CTMX
|
-28.7 M | $ 4.4 | - | $ 607 M | ||
|
Citius Pharmaceuticals
CTXR
|
-2.99 M | $ 0.86 | - | $ 5.79 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Cue Biopharma
CUE
|
-22.9 M | $ 0.18 | - | $ 17.1 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
DBV Technologies S.A.
DBVT
|
-188 M | $ 20.36 | - | $ 2.84 B | ||
|
AIkido Pharma
AIKI
|
-31.2 M | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
-5.53 M | - | -45.71 % | $ 1.2 M | ||
|
Denali Therapeutics
DNLI
|
-158 M | $ 19.38 | - | $ 3.19 B | ||
|
Dyadic International
DYAI
|
-6.38 M | $ 0.87 | -2.8 % | $ 31.5 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-5.45 M | $ 3.54 | - | $ 238 B | ||
|
Akouos
AKUS
|
-92.9 M | - | 0.23 % | $ 488 M | ||
|
Entera Bio Ltd.
ENTX
|
-7.85 M | $ 1.19 | - | $ 55.5 M | ||
|
Equillium
EQ
|
-29.6 M | $ 2.01 | - | $ 115 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 330.34 | - | $ 43.3 B | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Fate Therapeutics
FATE
|
31.2 M | $ 1.19 | - | $ 141 M | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M |